title: Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer.
abstract: Fourteen consecutive female patients with metastatic breast cancer received a total of 31 courses of fazarabine at a dose of 2 mg/m2/hour x 72 hours (48 mg/m2/day x 3) as a continuous infusion. There were no responses seen, although one patient achieved stability of her disease for five courses. Because of encouraging in vitro results and the primarily hematologic dose-limiting toxicity, further study in combination with colony stimulating growth factors might be of interest.
authors.affiliation: University of Texas M.D. Anderson Cancer Center, Department of Medical Oncology, Houston 77030.
authors.forename: R S
authors.initials: RS
authors.lastname: Walters
authors.forename: R L
authors.initials: RL
authors.lastname: Theriault
authors.forename: F A
authors.initials: FA
authors.lastname: Holmes
authors.forename: G N
authors.initials: GN
authors.lastname: Hortobagyi
authors.forename: L
authors.initials: L
authors.lastname: Esparza
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001374:Azacitidine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged
chemical_list: D000970:Antineoplastic Agents; C022121:fazarabine; D001374:Azacitidine